Prelude Therapeutics Incorporat (PRLD) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Prelude Therapeutics Incorporat

NasdaqGS•Healthcare•Biotechnology

$5.46+0.21(0.04%)Market closed

Market Cap

$439.80M

P/S

19.6x

P/B

3.3x

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCellera Biologics to discover, develop, and commercialize novel degrader antibody conjugates. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

How this company scores

AverageMetricSide Score: 57/100

Strongest: Growth (20/25); weakest: Cash & Earnings Quality (9/25).

Profitability13/25

Growth20/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality9/25

Strengths

Growing revenueInterest easily coveredProfit converts from growthConsistent growth

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 19.6x5y range 8.3x – 52.3x

Currently above its 8-quarter median.

P/B · 3.3x5y range 0.6x – 4.6x

Currently above its 20-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 7 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $439.80M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $22.42M
Q. Revenue: $5.70M
TTM EBITDA: $-65.81M
TTM Op. Income: $-67.40M
Q. Op. Income: $-15.45M
TTM Net Income: $-60.49M
Q. Net Income: $-13.92M
EPS: $-0.14
Shares Out.: $98.39M

$22.42M in TTM revenue grew 220.3% YoY, reaching $5.70M last quarter. TTM EBITDA of $-65.81M and TTM operating income of $-67.40M show growth is flowing through to the bottom line. However, net income is negative at $60.49M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has risen for 4 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: -264.7%
Op. Margin: -270.9%
Net Margin: -244.1%

Op. margin of -270.9% is up 3219399729.1% YoY — cost efficiency is improving. Net margin at -244.1% Over the past year, operating margin is up 100% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 19.6x
P/B Ratio: 3.3x

P/S of 19.6x and P/B of 3.3x. P/S is high, meaning growth expectations are priced in.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $189.36M
Cash: $26.33M
Long-Term Debt: N/A
Book Value: $133.73M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-15.57M
TTM Free Cash Flow: $-33.26M
FCF Margin: -148.3%
FCF / Net Income: 0.5

TTM FCF of $-33.26M on $-15.57M in operating cash flow. The FCF / Net Income ratio of 0.5x means cash covers only part of net income — earnings quality needs attention. Across the last 8 quarters, free cash flow has risen for 4 consecutive quarters — an improving trend.